Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CGEM with free AI briefings, catalyst countdowns, and dilution alerts.

CGEM · Cullinan Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$311.5M Cash on Hand
23mo Cash Runway
Follow CGEM by email Get an email when CGEM reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CGEM, unsubscribe in one click. Privacy

💊 Upcoming FDA Decisions

PDUFA DateDrugIndicationTypePoA
2027-02-27 Zipalertinib relapsed EGFR ex20ins NSCLC NDA 66%

PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →

📣 What CGEM Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Anti-FLT3/CD3 Bispecific Antibody CLN-049 Relapsed/Refractory Acute Myeloid Leukemia (AML) Phase 1/2 · NCT05143996 Recruiting
Zipalertinib (CLN-081) Non Small Cell Lung Cancer Phase 1/2 · NCT04036682 Active not recruiting
Velinotamig specified dose on specified days. Immune Thrombocytopenia (ITP) Phase 1/2 · NCT07738822 Not yet recruiting
EBNA-1 inhibitor VK-2019 Nasopharyngeal Carcinoma Phase 1/2 · NCT03682055 Terminated
Carboplatin AUC 6 Advanced Solid Tumor Phase 1 · NCT05117476 Active not recruiting
Isuventatug (CLN-619) Multiple Myeloma Phase 1 · NCT06381141 Active not recruiting
Anti-CD19/CD3 T-cell Engaging Bispecific… Sjögren Phase 1 · NCT07041099 Recruiting
Datopotamab Deruxtecan Advanced Solid Tumor Phase 1 · NCT05117476 Active not recruiting

Also used in these trials (approved or third-party drugs, not CGEM's own candidates): Azacitidine, IL-2/IL-12-based Fusion Protein CLN-617, Paclitaxel, Pembrolizumab, Pemetrexed Disodium, Venetoclax.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CGEM holds $311.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $40.7M/quarter from operations, an estimated runway of 23 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 41 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CGEM files for a raise →

👥 Who Owns CGEM

Insiders 15.3% Institutions (261 holders) 84.7% Public and other holders 0%
HolderTypeShares% of sharesAs of
Lynx1 Capital Management LP
10% owner
Insider 8,963,500 13.81% 2025-10-28
BVF PARTNERS L P/IL Institution (13G, 5%+) 6,491,123 10.00% 2026-06-30
T. Rowe Price Associates, Inc. Institution (13G, 5%+) 3,825,950 5.89% 2026-06-30
Kynam Capital Management, LP Institution (13G, 5%+) 3,114,132 4.80% 2025-12-31
Nadim Ahmed
President and CEO, Director · +828,000 options
Insider 390,803 0.60% 2026-02-24
Jeffrey Alan Jones
Chief Medical Officer · +300,000 options
Insider 159,968 0.25% 2026-02-24
Jennifer Michaelson
Chief Scientific Officer · +190,182 options
Insider 158,649 0.24% 2026-11-05
Jacquelyn L Sumer
Chief Legal Officer · +230,000 options
Insider 130,559 0.20% 2026-06-30
Mary Kay Fenton
Chief Financial Officer · +137,500 options
Insider 127,921 0.20% 2026-06-30

Share count 64,920,924 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full CGEM picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CGEM and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.